Study suggests sFcεRI may play a dual role in SM severity and protection
A new study reveals that sFcεRI acts as a biomarker of systemic mastocytosis severity while potentially protecting against anaphylaxis.
Lucia Rajcic
Master of Pharmacy (MPharm) with a strong background in clinical practice and pharmaceutical sciences. Dedicated to providing accurate, evidence-based medical content for healthcare professionals and patients.
